Recent translational studies have indicated more specifically that the interleukin (IL)‐17 pathway is a potential target for the effective treatment of moderate‐to‐severe HS15: Th17 cells are enriched in HS lesional skin,16 IL‐17A expression is elevated in HS compared with healthy skin,17, 18 and serum IL‐17A levels are also increased and correlate with HS disease severity.19 The gene discussed is IL17A; the disease is histiocytic sarcoma.